Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus ONMEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus ONMEL.
LODINE vs ONMEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
ONMEL (omacetaxine mepesuccinate) inhibits protein synthesis by binding to the 80S ribosome and interfering with chain elongation, leading to apoptosis in leukemic cells.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
50 mg orally twice daily for 14 days
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
Terminal half-life 40–60 hours (mean 50 hours); allows once-daily dosing for systemic antifungal therapy.
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; >90% eliminated as metabolites in bile and feces.
Category C
Category C
NSAID
NSAID